Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Aravive aggregated by PharmaCompass.com.

    Client Virtual Booth

    ARAVIVE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Aravive
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    LyondellBasell Tower 1221 McKinney Street Suite 3200 Houston, Texas 77010
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aravive.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Aravive, Inc. to Delist from The Nasdaq Stock Market
    Aravive, Inc. to Delist from The Nasdaq Stock Market

    https://www.globenewswire.com//news-release/2024/01/17/2811132/30446/en/Aravive-Inc-to-Delist-from-The-Nasdaq-Stock-Market.html

    GLOBENEWSWIRE
    17 Jan 2024
    Share Share
    Aravive, weeks from liquidation, lays off 70% of its staff
    Aravive, weeks from liquidation, lays off 70% of its staff

    https://www.fiercebiotech.com/biotech/aravive-weeks-liquidation-lays-70-its-staff-it-seeks-savior

    Nick Paul Taylor FIERCE BIOTECH
    22 Aug 2023
    Share Share
    Phase 3 cancer flop blows hole in plans of cast-strapped Aravive
    Phase 3 cancer flop blows hole in plans of cast-strapped Aravive

    https://www.fiercebiotech.com/biotech/araviv-ederci-phase-3-cancer-flop-blows-hole-plans-cast-strapped-biotech

    Nick Paul Taylor FIERCE BIOTECH
    03 Aug 2023
    Share Share
    Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept
    Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept

    https://www.globenewswire.com/news-release/2023/08/02/2717335/30446/en/Aravive-Announces-Top-Line-Results-from-Phase-3-AXLerate-OC-Study-of-Batiraxcept-in-Platinum-Resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    02 Aug 2023
    Share Share
    Aravive to Present Updated Clinical Data from Batiraxcept Trials
    Aravive to Present Updated Clinical Data from Batiraxcept Trials

    https://www.globenewswire.com/news-release/2023/07/28/2713027/30446/en/Aravive-to-Present-Updated-Clinical-Data-from-Batiraxcept-Trials-in-Renal-and-Pancreatic-Cancer-at-ESMO-Congress-2023.html

    GLOBENEWSWIRE
    28 Jul 2023
    Share Share
    Aravive to Participate in William Blair's Innovator Series
    Aravive to Participate in William Blair's Innovator Series

    https://www.globenewswire.com/news-release/2023/07/14/2704921/30446/en/Aravive-to-Participate-in-William-Blair-s-Innovator-Series-Transitioning-Biotech-Breakthroughs-to-Commercial-Success-Being-Held-July-18-2023.html

    GLOBENEWSWIRE
    14 Jul 2023
    Share Share
    Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
    Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)

    https://www.globenewswire.com/news-release/2023/06/13/2687645/30446/en/Aravive-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c.html

    GLOBENEWSWIRE
    13 Jun 2023
    Share Share
    Aravive To Participate in the Jefferies Global Healthcare Conference
    Aravive To Participate in the Jefferies Global Healthcare Conference

    https://www.globenewswire.com/news-release/2023/06/05/2682366/30446/en/Aravive-To-Participate-in-the-Jefferies-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    05 Jun 2023
    Share Share
    Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcep
    Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcep

    https://www.globenewswire.com/news-release/2023/05/25/2676762/30446/en/Aravive-to-Present-Promising-Updated-Data-from-Phase-2-Trial-of-Batiraxcept-in-Combination-with-Cabozantinib-in-Clear-Cell-Renal-Cell-Carcinoma-at-ASCO-2023.html

    GLOBENEWSWIRE
    25 May 2023
    Share Share
    Aravive Announces Ph3 Trial Design for Batiraxcept in Renal Cell Carcinoma
    Aravive Announces Ph3 Trial Design for Batiraxcept in Renal Cell Carcinoma

    https://www.globenewswire.com/news-release/2023/05/16/2669831/30446/en/Aravive-Announces-Phase-3-Trial-Design-for-Batiraxcept-in-Clear-Cell-Renal-Cell-Carcinoma.html

    GLOBENEWSWIRE
    16 May 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search